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Abstract
Objectives We tested whether complementary use of the somatostatin analogue pasireotide would augment efficacy of aspiration
sclerotherapy of hepatic cysts.
Methods We conducted a double-blind, placebo-controlled trial in patients who underwent aspiration sclerotherapy of a large (>5
cm) symptomatic hepatic cyst. Patients were randomized to either intramuscular injections of pasireotide 60 mg long-acting
release (n = 17) or placebo (sodium chloride 0.9 %, n = 17). Injections were administered 2 weeks before and 2 weeks after
aspiration sclerotherapy. The primary endpoint was proportional cyst diameter reduction (%) from baseline to 6 weeks.
Secondary outcomes included long-term cyst reduction at 26 weeks, patient-reported outcomes including the polycystic liver
disease-questionnaire (PLD-Q) and safety.
Results Thirty-four patients (32 females; 53.6 ± 7.8 years) were randomized between pasireotide or placebo. Pasireotide did not
improve efficacy of aspiration sclerotherapy at 6 weeks compared to controls (23.6 % [IQR 12.6–30.0] vs. 21.8 % [9.6–31.8];
p = 0.96). Long-term cyst diameter reduction was similar in both groups (49.1 % [27.0–73.6] and 45.6 % [29.6–59.6]; p = 0.90).
Mean PLD-Q scores improved significantly in both groups (p < 0.01) without differences between arms (p = 0.92).
Conclusions In patients with large symptomatic hepatic cysts, complementary pasireotide to aspiration sclerotherapy did not
improve cyst reduction or clinical response.
Key Points
• Complementary pasireotide treatment does not improve efficacy of aspiration sclerotherapy.
• Cyst fluid reaccumulation after aspiration sclerotherapy is a transient phenomenon.
• Aspiration sclerotherapy strongly reduces symptoms and normalizes quality of life.
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Introduction
Hepatic cysts are fluid-filled cavities in the liver that congen-
itally arise from aberrant cholangiocytes [1]. Cysts occur in a
spectrum from sporadic lesions to numerous cysts as part of
polycystic liver disease (PLD). Due to continuous epithelial
cell proliferation and fluid production, cysts grow over time
[2, 3]. Large hepatic cysts lead to invalidating symptoms as
pain, nausea and dyspnoea due to mechanical compression of
surrounding organs that ultimately compromise the patients’
quality of life [4–6].
Aspiration sclerotherapy is a minimally invasive procedure
aimed at reducing the volume of these fluid-filled lesions [7].
Injecting ethanol (or other sclerosing agents) directly in the
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cyst cavity destroys the inner cyst-lining epithelium [8–10].
Lysis of these epithelial cells halts cell proliferation and cyst
fluid production [11]. Aspiration sclerotherapy generally
reaches favourable results in solitary cysts or dominant cysts
in PLD [7]. However, reported long-term efficacy of cyst re-
duction is mixed and ranges from complete regression to re-
currence of the cyst [12, 13]. An important predictor of cyst
reduction is the extent of intracystic fluid reaccumulation after
treatment [14]. Typically, cyst fluid reaccumulates in the first
weeks after treatment [15]. It is hypothesized that this transient
fluid productionmay result from remnants of the cyst wall that
are not eliminated by sclerotherapy [16]. This initial fluid
relapse threatens long-term efficacy and may lead to recur-
rence of the cyst necessitating re-intervention [14, 15].
Somatostatin analogues inhibit cyst fluid production and
cell proliferation by activating somatostatin receptors on the
basolateral surface of the cyst [3, 17]. Previous studies showed
that lanreotide and octreotide reduce cystic volume in patients
with polycystic liver disease [18, 19]. Pasireotide (SOM230)
is a more potent somatostatin analogue due to a broader bind-
ing profile and higher affinity to somatostatin receptor sub-
types [20].
Adjuvant treatment of pasireotide with aspiration sclero-
therapy has the promise of curtailing fluid reaccumulation
and reducing cholangiocyte proliferation. This strategy has
precedence as surgeons have described the use of octreotide
after surgical cyst fenestration in an observational study (n = 5)
and observedminimized fluid production by exposed remnants
of fenestrated cysts leading to apparent control of ascites [21].
We hypothesized that the combined approach of aspiration
sclerotherapy and pasireotide would decrease fluid accumula-
tion and improve long-term cyst reduction and clinical re-
sponse. Therefore, the purpose of this study was to test wheth-
er pasireotide could improve the efficacy of aspiration sclero-
therapy of large symptomatic hepatic cysts.
Materials and methods
This study was performed following approval by the
Institutional Review Board (Medical Research Ethics
Committee of the region Arnhem-Nijmegen) and conformed
to the ethical guidelines of the 1975 Declaration of Helsinki.
The trial was registered at ClinicalTrials.gov (NCT02048319).
We previously reported a detailed protocol elsewhere [22]; a
brief description is given below.
Study design and participants
This randomized, single-centre, double-blind, placebo-
controlled trial was carried out in the Radboud University
Centre, Nijmegen, The Netherlands between April 2014 and
April 2016. Trial duration was 26 weeks. Following written
informed consent, we randomized patients in a 1:1 ratio to
pasireotide or placebo. Randomization was concealed to pa-
tients and investigators.
Patients aged between 18 and 70 years with a large (> 5 cm)
symptomatic solitary or dominant hepatic cyst were eligible
for participation. A dominant cyst was regarded as the largest
cyst within PLD. Major exclusion criteria were: a complicated
cyst (neoplastic or hydatid cyst), a prolonged corrected QT-
interval (> 470 ms), symptomatic cholecystolithiasis, uncon-
trolled diabetes (HbA1C > 64 mmol/mol) and surgical or ra-
diological cyst interventions within 6 months prior to the
study.
Study procedures
All patients received aspiration sclerotherapy. In brief, we per-
formed a single-session sclerotherapy procedure. The proce-
dure was performed using conscious sedation with propofol
(propofol 10 mg/ml, Fresenius, Bad Homburg vor der Höhe,
Germany) and alfentanyl (rapifen, 5 mg/10 ml, Tilburg,
The Netherlands). Guided by ultrasound, the interventional
radiologist inserted a 5 French pigtail catheter (Cook
Medical, Bloomington, IL, USA) in the cyst and performed
fluid drainage until collapse of the cyst. Cyst leakage was
ruled out by instillation of contrast medium (Iomeron 300,
Bracco Imaging, Konstanz, Germany, up to 20 ml) followed
by 10-min sclerotherapy. We injected 100 % ethanol in a 10%
ratio of the aspirated cyst volume (up to 50 ml) [23]. All
patients were hospitalized for 24-h observation.
The intervention arm received 60 mg pasireotide
(SOM230, Novartis, Basel, Switzerland) long-acting release
(LAR). This formulation is injected intramuscularly and se-
cures an extended-release depot suitable for monthly admin-
istration [20]. Based on its pharmacokinetic profile we admin-
istered pasireotide 2 weeks before and 2 weeks after aspiration
sclerotherapy to reach optimal drug levels around the proce-
dure. Controls received placebo injections of sodium chloride
0.9 % (Fresenius Kabi, Hesse, Germany) at equal time points:
2 weeks before and 2 weeks after aspiration sclerotherapy.
Injections were omitted if safety laboratory margins (fasting
blood sugar, alanine aminotransferase, aspartate aminotrans-
ferase, bilirubin and amylase) were exceeded [22]. Injections
were administered by unblinded healthcare professionals not
involved in the design or analysis of this trial.
Study endpoints
The primary outcome was the mean proportional change (%)
in cyst diameter of the treated hepatic cyst from baseline to
week 6, as measured by ultrasonography. Secondary out-
comes were change in cyst diameter at 14 and 26 weeks; cyst
volume reduction at 6, 14 and 26 weeks; recurrence rate (< 20
% reduction) at 6 and 26 weeks; patient-reported outcomes
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(change in symptoms and health-related quality of life) at 6
and 26 weeks; and rate and severity of adverse events during
trial participation.
Ultrasonography measurement
All ultrasound measurements were performed by the primary
blinded operator (TW) using a 3.5 MHz convex transducer
(Acuson X150TM, Siemens Healthcare, Erlangen, Germany).
At baseline, the indicated cyst was visualized in two planes to
measure the maximal orthogonal diameters, from which we
calculated one mean diameter (Supplementary Fig. 1). In ad-
dition, cyst volume was estimated by the ellipsoid volume
formula (D1*D2*D3*0.523) [15]. In case of a dominant cyst,
the segmental location and surrounding structures (cysts and
vessels) were closely documented to secure identification of
the treated cyst at follow-up. Measurements were repeated at
weeks 6, 14 and 26 to obtain the proportional (%) change. A
second blinded independent operator (ML) repeated all mea-
surements of all patients to assess interobserver variability. In
addition, the primary operator repeated measurements in a
subset of nine patients to evaluate intra-observer variability.
Patient-reported outcomes
To evaluate symptoms, patients completed the Polycystic
Liver Disease-Questionnaire (PLD-Q), which assesses fre-
quency and discomfort of 13 PLD-related symptoms over a
timeframe of one month [24]. Scores can be compiled to a
total sumscore from 1 (asymptomatic) to 100 (severe symp-
tomatic) points. To evaluate health-related quality of life
(HRQL) we used the generic Medical Outcomes Study 36-
item short-form health survey (SF-36) [25]. Scores were sum-
marized to a norm-based physical (PCS) and mental compo-
nent score (MCS), with a general population reference of 50 ±
10 [26]. Lower PCS or MCS scores indicate a compromised
HRQL [27].
Statistical analysis
Based on data from a previous cohort [28], we expected 30 %
cyst diameter reduction 4 weeks after aspiration sclerotherapy.
We hypothesized that this reduction at 4 weeks would be
improved to 50 % by adjuvant treatment with pasireotide. In
order to detect a statistical difference between groups, we
needed a sample size of 34 participants (power: 80 %; α:
0.05; drop-out rate: 10 %). Intention-to-treat analysis was per-
formed including all patients who received at least one dose of
pasireotide. In addition, a parallel per-protocol analysis was
conducted in patients who received both injections and aspi-
ration sclerotherapy. Values were reported as median with
interquartile range. For continuous endpoints, we calculated
differences between arms using the Mann-Whitney U test. To
correct for baseline diameter differences and underlying diag-
nosis (solitary cyst or PLD) between arms, we performed a
sensitivity analysis using ANCOVA. The Wilcoxon signed-
rank test was used to compare within-group differences. Cyst
recurrence was compared between groups by Fisher’s exact
test. In case of a missing variable, we carried the last available
value forward. Summarizing scores of patient-reported out-
comes (PLD-Q sumscore, PCS, MCS) were compared be-
tween groups after treatment. To assess safety, we compiled
frequency tables for adverse events classified according to
WHO adverse reaction terminology. Statistical analyses were
performed prior to unblinding using SPSS (version 22.0;
SPSS, Chicago, IL, USA). Analyses were two-sided with a
p-value < 0.05 considered statistically significant.
Results
Baseline characteristics
We screened 71 consecutive patients with symptomatic hepat-
ic cysts for eligibility. Of these, 28 patients did not meet the
inclusion criteria and nine patients declined to participate (Fig.
1). In total, 34 participants (female n = 32, male n = 2) were
randomly assigned to either pasireotide or placebo. Baseline
characteristics are shown in Table 1.
All subjects were included in the intention-to-treat analysis.
One aspiration sclerotherapy procedure failed as the targeted
cyst could not be punctured due to a deep cranial position.
This patient did not receive a second injection. In both groups
one patient did not receive a second injection due to adverse
events (hyperglycaemia and dizziness). Finally, one patient
(pasireotide-arm) had a second aspiration sclerotherapy pro-
cedure at week 24 due to ongoing severe complaints. From
another patient (placebo-arm), the treated cyst could not be
identified from other cysts at week 26. Findings at week 14
of these two patients were carried forward to week 26 for
analysis.
Primary outcome
Intention-to-treat analysis
Median cyst diameter in the pasireotide-arm decreased by
23.6 % (interquartile range [IQR] 12.6–30.0) compared to
21.8 % (IQR 9.6–31.8) in patients assigned to placebo (Fig.
2). Proportional diameter reduction was similar (p = 0.96)
between groups. When corrected for baseline diameter and
diagnosis by ANCOVA, proportional reduction remained
equal (p = 0.64).
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Per-protocol analysis
The three patients who did not receive a second injection were
excluded from per-protocol analysis, resulting in a sample of
31 patients (Fig. 1). In the pasireotide-sample (n = 15), cyst
diameter reduced by 23.6 % (IQR 15.8–32.0) compared to
22.6 % (IQR 12.4–32.4) in patients receiving placebo (n =
16). Similar to the intention-to-treat analysis, we found no
statistical significant difference between groups (p = 0.83).
Intra- and interobserver variability
We found a mean difference of 0.45 % ± 2.72 % between
measurements of the primary operator with an intraclass coef-
ficient of r = 0.99 (p < 0.01). Compared to measurements of
the second operator there was a mean difference of 1.75 % ±
5.30 %, with an intraclass coefficient of r = 0.97 (p < 0.01).
Secondary outcomes
Long-term cyst diameter reduction
The two groups showed similar progressive long-term diam-
eter reduction (Fig. 3). At week 14, median proportional cyst
diameter reduction was 37.5 % (IQR 24.0–52.6) in patients
assigned to pasireotide and 30.3 % (IQR 19.5–48.4) in con-
trols (p = 0.84). At week 26, treated cyst diameters had further
reduced to 49.1 % (IQR 27.0–73.6) (pasireotide) and 45.6 %
(IQR 29.6–59.6) (placebo) compared to baseline (p = 0.90;
Supplementary Table 1).
Volume reduction and cyst recurrence
Changes in volume from baseline to 26 weeks are shown in
Fig. 3. Similar to diameter results, groups achieved compara-
ble volume reduction rates (Supplementary Table 2). In both
groups, 8/17 (47 %) patients showed cyst recurrence at week
6. This decreased to one patient in the pasireotide group and
two patients in the placebo group at the end of the trial (p =
0.6).
Patient-reported outcomes
Total PLD-Q score showed a statistically significant (p < 0.01)
decrease over time in both groups indicating symptomatic
improvement (Fig. 4). Final PLD-Q improvement was
Fig. 1 Flow diagram. ITT
intention-to-treat, PP per-protocol
Table 1 Demographics and baseline characteristics
Pasireotide (n = 17) Placebo (n = 17)
Age at treatment, years 54 [51–61] 50 [45–61]
Female sex, n 16 (94) 16 (94)
PLD (>20 cysts), n 10 (59) 13 (76)
Baseline cyst diameter, cm 10.4 [8.2–13.4] 9.0 [7.1–10.8]
Baseline cyst volume, ml 529.8 [288.4–1027.1] 378.2 [188.5–635.7]
BMI, kg/m2 27.3 [25.1–30.2] 23.2 [22.2–27.4]
Continuous data are reported as median [interquartile range], absolute
numbers as n (%)
PLD polycystic liver disease, BMI body mass index
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comparable between groups (p = 0.95; Supplementary
Table 3). At baseline, the physical domain of HRQL was
restricted at baseline in both arms. After treatment, PCS im-
proved in both groups with a statistically significant effect in
the pasireotide sample (p < 0.01). Nonetheless, PCS at week
26 was similar among arms (p = 0.43). Baseline MCS was
slightly restricted in the pasireotide group and normal in con-
trols. In both groups the MCS increased; however, the final
MCS was similar (p = 0.56).
Adverse events
There were four serious adverse events requiring hospital ad-
mission. One female patient developed a cyst-bleeding 10
days after aspiration sclerotherapy that was treated with anal-
gesics. A male patient developed urolithiasis that was treated
surgically. Furthermore, a female patient developed pneumo-
nia, which was treated with antibiotics and analgesics. Finally,
a female patient underwent a second aspiration sclerotherapy
of the treated cyst due to ongoing severe abdominal distension
and inadequate cyst reduction from the first procedure.
The most common adverse event was abdominal pain
(pasireotide n = 13; placebo n = 11), which was mild and
self-limiting in 20 cases (Table 2). In the remaining four cases,
pain was more severe (grade III) and analgesics were needed
to relieve symptoms. Glucose levels in the pasireotide group
rose from 5.3 mmol/L (IQR 5.1–6.1 mmol/L) to 6.8 mmol/L
(IQR 6.6–7.7 mmol/L) at week 4 (p < 0.01) and normalized at
the end of follow-up. By contrast, median levels in patients on
placebo did not differ over time (Supplementary Fig. 2).
Discussion
The key finding of this study is that a pre- and postprocedural
intramuscular injection of pasireotide LAR in addition to aspi-
ration sclerotherapy does not improve cyst reduction or clinical
outcomes compared to controls. In both arms, we found symp-
tomatic relief and normalized HRQL, underlining the clinical
benefit that can be achieved by aspiration sclerotherapy.
We expected that a combined approach to target cysts, i.e.
pasireotide and aspiration sclerotherapy, would enhance efficacy
over mere aspiration sclerotherapy. This hypothesis was based
upon the working mechanism of somatostatin analogues.
Somatostatin analogues lower intracellular levels of 3’-5’-cyclic
adenosine monophosphate (cAMP) by binding somatostatin re-
ceptors (SSTR) [3, 17]. This second messenger cAMP stimu-
lates cyst fluid production by activating chloride (cystic fibrosis
transmembrane conductance regulator; CFTR) and water (aqua-
porin 1) channels on the apical side of the cyst epithelial cells
[29]. In addition, cAMP stimulates cell hyperproliferation lead-
ing to cyst growth [30, 31]. Therefore, by lowering intracellular
levels of cAMP, cyst fluid production is curtailed and epithelial
cell proliferation suppressed, collectively leading to cyst regres-
sion [17, 31]. Previous clinical studies showed how somatostatin
analogues reduce polycystic liver volume [18].We expected that
these features would reduce post-intervention fluid
reaccumulation and improve long-term cyst reduction.
Fig. 3 Cyst diameter (A) and volume (B) reduction from baseline to weeks 6, 14 and 26 compared between pasireotide and placebo
Fig. 2 Primary outcome. Diameter reduction compared to baseline at
week 6
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Nonetheless, we found no differences between groups. Our
efficacy results were comparable with other studies that per-
formed mere aspiration sclerotherapy [7]. Why was our hy-
pothesis not recapitulated by the results of our study? First,
while other somatostatin analogues such as lanreotide and
octreotide decrease hepatic cyst volumes, it is possible that
pasireotide does not inhibit hepatic cystogenesis in humans.
Compared to conventional somatostatin analogues, pasireotide
has a broader binding profile (octreotide SSTR 2, 3, and SSTR5;
pasireotide SSTR 1,2,3, and SSTR5) and a higher affinity to
SSTR 1, 3 and SSTR5 [20]. Based on this pharmacological
profile, it is reasonable to assume that pasireotide also reduces
cyst progression in humans. However, no human studies have
reported the effects of pasireotide on hepatic cysts. Currently, a
randomized clinical trial is being conducted to investigate the
efficacy of pasireotide in polycystic liver disease, which will
provide better insight into the cyst-reducing properties of
pasireotide (Clinicaltrials.gov; NCT01670110).
In addition, we may have administrated pasireotide in an
inadequate dosage or regimen to be effective. In order to op-
timize the efficacy/safety balance we targeted our patients
with pasireotide in a limited period before and after the pro-
cedure. To reach optimal drug levels, we administered a dos-
age of 60 mg in a long-acting release formulation. This is the
highest available dosage within the safety range [32, 33]. The
mild hyperglycaemia that followed pasireotide injections sug-
gests adequate exposure to the drug.
Finally, the process of post-procedural cyst fluid
reaccumulation leading to recurrence may not be affected by
pasireotide. Alternatively, it is hypothesized that fluid
reaccumulation results from an inflammatory response in-
duced by cell lysis following sclerotherapy, rather than fluid
production of remaining functional cyst epithelium [13]. An
exploratory study repunctured treated cysts 2–8 days follow-
ing aspiration sclerotherapy and observed an increase in leu-
kocytes compared to the primary aspirate, suggesting ongoing
inflammation [34].
Traditionally, efficacy studies of aspiration sclerotherapy
focused on the technical (morphological) response of aspira-
tion sclerotherapy [5, 7]. As hepatic cysts are benign lesions,
indication for treatment is driven upon the patient’s symptom-
atology. This was the first study to assess patient-reported
outcomes at standardized time points using validated instru-
ments. At baseline, we found low physical SF-36 scores and
increased PLD-Q scores indicating a restricted HRQL a
Fig. 4 Symptomatic
improvement from baseline to
week 26 (T26), assessed by the
disease-specific Polycystic Liver
Disease Questionnaire (PLD-Q)
leading to a summarizing score.
The dotted line (reference)
indicates the general population
score
Table 2 Adverse events
Pasireotide (n = 17) Placebo (n = 17)
Total Grade 3 Total Grade 3
Hyperglycaemia 17 (100) 0 5 (29) 0
Abdominal pain 13 (76) 1 (6) 11 (65) 3 (18)
Loose stools 13 (76) 0 10 (58) 0
Fatigue 10 (58) 0 7 (41) 0
Nausea 8 (47) 0 6 (35) 0
Skin response injection site 6 (35) 0 1 (6) 0
Palpitations 4 (24) 0 1 (6) 0
Vomiting 3 (18) 0 1 (6) 0
Decreased satiety 3 (18) 0 1 (6) 0
Overall malaise 3 (18) 0 1 (6) 0
Menstruation disorders1 2 (13) 0 0 0
Dizziness 2 (12) 0 2 (12) 0
Thrombotic events2 2 (12) 1 0 0
Pneumoniae/pneumonitis 1 (6) 0 1 (6) 1 (6)
Urolithiasis 1 (6) 1 (6) 0 0
Serious adverse events3 2 (12) 2 (12)
Values are given as number (percent)
1 Prolonged period (n = 1); irregular menstruation (n = 1)
2 Thrombosis vena subclavia after peripheral catheter left arm (n = 1);
superficial thrombosis lower right leg (n = 1)
3 Serious adverse events: cyst bleeding (n = 1); urolithiasis (n = 1); re-
intervention hepatic cyst (n = 1); pneumonia (n = 1)
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symptomatic burden compared to general population refer-
ences [26]. In this study we demonstrated that aspiration
sclerotherapy significantly reduces disease-specific symptoms
and normalizes HRQL. These findings support the notion that
aspiration sclerotherapy is an excellent first-line choice to treat
patients with large symptomatic hepatic cysts.
The strength of this study is that we combined an invasive
and medical strategy to optimize cyst reduction in a clinical
trial design. This study also has several limitations. Firstly, our
primary endpoint was measured by ultrasonography, which
introduces variability as it is operator-dependent. CT or MRI
may reduce variability, but would have led to unnecessary
exposure to radiation and/or costs as this study required mul-
tiple measurements within short intervals. To minimize bias,
all measurements were performed by the same investigator
following standardized operating procedures. As a result, we
found excellent intraclass coefficients of intra- and interob-
server variability [35]. Secondly, we powered our study as-
suming a large beneficial effect from pasireotide. Possible
smaller differences between our groups cannot be ruled out.
However, we believe that such small differences would not be
relevant for clinical practice, given the costs of pasireotide.
Finally, we included both sporadic hepatic cysts and dominant
hepatic cysts within PLD. The genetic background of both
congenital cyst types corresponds as somatic loss of PLD-
type alleles from cyst epithelium is required to drive cyst for-
mation [36]. Indeed, both cyst types have a thin wall lined by a
single layer of aberrant cholangiocytes, which are targetable
by somatostatin analogues [4, 37]. However, it is unclear if
germline mutations in PLD patients alter susceptibility to
these agents. In our study, we found no differences in efficacy
between patients with or without underlying PLD, as reflected
in the previous literature [8].
In summary, adjuvant pasireotide treatment to aspira-
tion sclerotherapy in patients with large hepatic cysts is
no more effective than aspiration sclerotherapy alone.
Aspiration sclerotherapy normalizes HRQL-rates
and decreases symptomatic disease, which proves aspira-
tion sclerotherapy is an excellent choice of therapy for
large hepatic cysts.
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